Upregulation of ARHGAP30 attenuates pancreatic cancer progression by inactivating the β-catenin pathway.

ABSTRACT:

Background

Pancreatic cancer is a highly malignant gastrointestinal cancer that can widely metastasize during the early stage of disease, and it is associated with one of the worst prognoses among cancers. In this study, we aimed to investigate the function of Rho GTPase-activating protein 30 (ARHGAP30) in pancreatic cancer cells and thus propose a novel therapy for pancreatic cancer.

Methods

ARHGAP30 expression in tumor tissues from patients with pancreatic cancer as well as cell lines was detected using immunohistochemistry (IHC), real-time polymerase chain reaction, and western blotting. Cell proliferation, transwell, and apoptosis assays were performed and the levels of related proteins were determined after ARHGAP30 knockdown or overexpression. Additionally, in vivo exp

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC7288688 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature